The remaining six included a CLL who recently stopped a BTK inhibitor, a myelodysplasia (MDS) on azacitidine, a cholangiocarcinoma on chemotherapy, an 85 year old with prostate cancer, an 86 year old with metastatic melanoma on temozolomide, and a metastatic renal cell carcinoma on axitinib and pembrolizumab. Here, BTK is linked to prostate cancer.